ALR Technologies SGALRTF +14.86% 3-Year ROIIC % is 11.87 as of Dec. 2025, which is 13% above its 10-year median of 10.48. The stock has 3 warning signs investors should review. Among 799 Medical Devices & Instruments companies, ALR Technologies SG ranks better than 62.45% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
ALR Technologies SG's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 11.87%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for ALR Technologies SG's 3-Year ROIIC % or its related term are showing as below:
ALRTF's 3-Year ROIIC % is ranked better than 62.45% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 1.67
vs ALRTF: 11.87
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
ALR Technologies SG 3-Year ROIIC % Related Terms
ALR Technologies SG 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for ALR Technologies SG's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALRTF vs CODX, SINT, HSCS: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, ALR Technologies SG's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALR Technologies SG 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ALR Technologies SG's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where ALR Technologies SG's 3-Year ROIIC % falls into.
ALR Technologies SG's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -2.881 (Dec. 2025) - -4.21 (Dec. 2022) )
/
( 32.281 (Dec. 2025) - 21.083 (Dec. 2022) )
=
1.329
/
11.198
=
11.87%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
ALR Technologies SG (ALRTF) has a 3-Year ROIIC % of 11.87 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ALR Technologies SG and its competitors. This is 13% above median its historical median of 10.48. According to the industry distribution chart, ALR Technologies SG ranks #300 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 37.5%.
Is ALR Technologies SG's 3-Year ROIIC % too high?
ALR Technologies SG's current 3-Year ROIIC % of 11.87 is 13% above median its 10-year median of 10.48. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.67. ALR Technologies SG's value of 11.87 is 610.8% above this industry median. Based on the distribution chart, ALR Technologies SG ranks #300 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does ALR Technologies SG's 3-Year ROIIC % compare to CODX and SINT?
According to the Medical Devices & Instruments industry distribution chart, ALR Technologies SG ranks #300 out of 799 companies for 3-Year ROIIC %. This puts ALR Technologies SG in the upper half of its industry. The industry median 3-Year ROIIC % is 1.67. ALR Technologies SG's value of 11.87 is 610.8% above this benchmark. While the company's 10-year median is 10.48 vs. the industry median of 1.67, ALR Technologies SG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.67, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ALR Technologies SG's current 3-Year ROIIC % of 11.87 is 610.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on ALR Technologies SG and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ALR Technologies SG's current 3-Year ROIIC % is 11.87, which is 13% above median its own 10-year median of 10.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALR Technologies SG stock overvalued right now?
ALR Technologies SG (ALRTF) has a current 3-Year ROIIC % of 11.87. The current 3-Year ROIIC % is 11.87, which is 13% above median its 10-year median of 10.48 and 610.8% above the Medical Devices & Instruments industry median of 1.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For ALR Technologies SG (ALRTF), the current 3-Year ROIIC % is 11.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALR Technologies SG Ltd is a medical device company that focuses on commercializing its Health-e-Connect System. The company is a data management company that developed a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA-compliant Diabetes Solution product that can collect data from BGM and CGM; a patent-pending Predictive A1C algorithm to track treatment success between lab reports; and an FDA-cleared Insulin Dosing Adjustment program. Geographically, it operates in the United States and Singapore.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALRTF has been successfully added to your 